Business Context and Reporting Period
Company: MIMEDX GROUP, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: December 27, 2011 (Signed January 3, 2012)
Event: Entry into a Material Definitive Agreement involving a private placement of debt securities.
Key Financial Metrics and Transaction Details
- Proceeds Raised: $5,000,000 aggregate principal from 13 accredited investors.
- Instrument: 5% Convertible Senior Secured Promissory Notes.
- Interest Rate: 5% per annum, payable quarterly in cash.
- Maturity Date: December 31, 2013.
- Conversion Terms: Convertible into up to 5,000,000 shares of Common Stock at $1.00 per share.
- Additional Interest: If not repaid by December 31, 2012, an additional 5% of the outstanding principal is due.
- Collateral: First priority lien on all patents and intellectual property (excluding specific assets related to the Surgical Biologics, LLC acquisition until those prior notes are paid).
- Placement Fees: $79,016 total ($32,800 cash + $46,216 in warrants).
Material Changes and Warrant Issuances
The filing details the issuance of three types of warrants to lenders, creating potential future dilution:
- Conversion Warrants: Issued to each lender for shares equal to the principal conversion amount (max 5,000,000 shares). Exercise price: $1.00. Exercisable only if the note principal is prepaid prior to maturity. Expires December 31, 2013.
- First Contingent Warrant: Issued for 25% of the shares issuable upon principal conversion (max 1,250,000 shares). Exercise price: $0.01. Condition: Exercisable only if 2011 gross revenues do not exceed $11,500,000.
- Second Contingent Warrant: Issued for 25% of the shares issuable upon principal conversion (max 1,250,000 shares). Exercise price: $0.01. Condition: Exercisable only if 2012 gross revenues do not exceed $31,150,000 AND the stock price does not trade at or above $1.75 for 10 consecutive days between measurement dates.
Related Party Transaction: $500,000 of the Notes were sold to Parker H. Petit, the Company's Chairman and CEO, fulfilling a prior commitment to lend up to $1,500,000 if other lenders did not subscribe.
Guidance, Risks, and Contingencies
- Revenue Contingencies: The exercisability of the Contingent Warrants is directly tied to the Company failing to meet specific gross revenue targets for 2011 ($11.5M) and 2012 ($31.15M).
- Change in Control: Contingent Warrants become immediately exercisable prior to a Change in Control Transaction if the per-share consideration is less than $1.75. If the consideration is $1.75 or more, the Second Contingent Warrant is null and void.
- Liquidity and Default: The Notes may be accelerated upon certain Events of Default. The lien is pari passu with the Company's existing Revolving Line of Credit held by the CEO.
- Registration Rights: Shares issued upon exercise of warrants do not carry registration rights.
Investor Verification Checklist
- Verify the Company's actual gross revenues for the year ended December 31, 2011, to determine if the First Contingent Warrants are exercisable.
- Monitor the stock price to see if it reaches $1.75 for 10 consecutive trading days, which would void the Second Contingent Warrants.
- Review the status of the $1,250,000 prior notes issued to Surgical Biologics, LLC, as their repayment affects the collateral pool for the new Notes.
- Confirm the total number of shares outstanding post-conversion, considering the potential issuance of up to 7,500,000 shares via warrants and note conversion.
- Assess the Company's ability to service the quarterly cash interest payments and the potential additional 5% interest due in 2012.